Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Pendulum Therapeutics

Explore full profile

Microbiome company focused on enabling better patient care through targeted equilibration of human microbiomes

San Francisco, United StatesFounded 2012Biotech & Life Sciences
Valuation $100–250M Last recorded · 2023
Revenue $10–50M Latest reported FY
Headcount 100–500 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Pendulum Therapeutics and the history behind them.

About Pendulum Therapeutics

Pendulum Therapeutics is a biotechnology company focused on improving metabolic health by targeting the gut microbiome. The company develops and markets medical probiotics, which are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.

The company's flagship product is Pendulum Glucose Control, a medical food designed to help manage blood sugar levels in people with type 2 diabetes. This product is a blend of five specific strains of beneficial bacteria, including Akkermansia muciniphila, which has been shown to be important for gut health. The company also offers other probiotic and synbiotic products targeting various aspects of gut and metabolic health, such as GLP-1 Probiotic, Metabolic Daily, and Polyphenol Booster.

Pendulum Therapeutics operates on a direct-to-consumer business model, selling its products through its website. The company also offers a subscription-based membership program that provides customers with regular deliveries of its products at a discounted price. The company's target market includes individuals with type 2 diabetes, prediabetes, and those looking to improve their overall metabolic and gut health.

The company's products are backed by scientific research, including clinical studies that have been published in peer-reviewed journals. Pendulum Therapeutics has also established strategic partnerships with other companies in the nutrition and health space, such as a partnership with Fonterra, a global nutrition science leader.

Source: Dealroom company data

At a glance

Founded
2012
Headquarters
San Francisco, United States
Sector
Biotech & Life Sciences
Power Law
Colt$25–100M revenue

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Mercuri

Series A5 investors entered at this stage

Series B and later1 investor entered at this stage

  • Nutrition Science Solutions
Employees mapped 110 incl. 5 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 8 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇺🇸 United States95.8%
🇨🇦 Canada1%
🇮🇳 India1%
🇳🇱 Netherlands1%
🇵🇭 Philippines1%
5 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Pendulum Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Pendulum Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.